Reprocell Europe Limited
Technical testing and analysis · Glasgow
ActiveUnited KingdomIncorporated 2002Private Limited Company
Documents & history
Available account evidence and business events. This is not a complete filing history or document library.
No electronic account filings
No extracted electronic accounts are available in our records.
Registered details
SC231284- Status
- Active
- Type
- Private Limited Company
- Incorporated
- 2002-05-09
- Jurisdiction
- —
- Registered office
- 4TH FLOOR, LOMOND HOUSE, 9 GEORGE SQUARE, GLASGOW, G2 1DY, SCOTLAND
Classification
1 SIC codes71200
Capital & company events
Reconstructed equity rounds and matched research funding.
Equity fundraising
0 SH01-derived roundsNo reconstructed allotment rounds.
Research and innovation
11 matched grantsGeneration of clinical grade human pluripotent stem cells (iPSCs) using safe mRNA reprogramming strategy: extensionLead
Innovate UK · Feasibility Studies · 2020-06-01 – 2020-11-30
£27,000
awarded
Generation of clinical grade human pluripotent stem cells (iPSCs) using safe mRNA reprogramming strategyInnovate UK · Collaborative R&D · 2018-10-01 – 2021-12-31 · with 1 other participant£119,469awarded
Generation of clinical grade human pluripotent stem cells (iPSCs) using safe mRNA reprogramming strategy
Innovate UK · Collaborative R&D · 2018-10-01 – 2021-12-31 · with 1 other participant
£119,469
awarded
Reprocell Europe Limited£119,469
Generation of clinical grade human pluripotent stem cells (iPSCs) using safe mRNA reprogramming strategyISCF · Collaborative R&D · 2018-09-30 – 2021-12-31 · with 1 other participant£869,739whole project
Generation of clinical grade human pluripotent stem cells (iPSCs) using safe mRNA reprogramming strategy
ISCF · Collaborative R&D · 2018-09-30 – 2021-12-31 · with 1 other participant
£869,739
whole project
Roslin Cell Therapies LimitedleadReprocell Europe Limited
Novel manufacture and commercialisation of a 96-well 3D skin model for drug and toxicology testingInnovate UK · Collaborative R&D · 2017-08-01 – 2019-07-31 · with 1 other participant£59,749awarded
Novel manufacture and commercialisation of a 96-well 3D skin model for drug and toxicology testing
Innovate UK · Collaborative R&D · 2017-08-01 – 2019-07-31 · with 1 other participant
£59,749
awarded
Reprocell Europe Limited£59,749
Novel manufacture and commercialisation of a 96-well 3D skin model for drug and toxicology testingISCF · Collaborative R&D · 2017-07-31 – 2019-07-30 · with 1 other participant£203,945whole project
Novel manufacture and commercialisation of a 96-well 3D skin model for drug and toxicology testing
ISCF · Collaborative R&D · 2017-07-31 – 2019-07-30 · with 1 other participant
£203,945
whole project
Alcyomics LimitedleadReprocell Europe Limited
Fresh native human tissue slices in 96-well plate fomat compatible with phenotypic high content biology for drug screening and advanced target validationLead
Innovate UK · Feasibility Studies · 2015-06-01 – 2015-09-30
£23,100
awarded
PatLead
Innovate UK · EU-Funded · 2013-09-01 – 2016-12-31
£259,973
awarded
PatLead
EU · EU-Funded · 2013-08-31 – 2016-12-31
£259,973
whole project
Pat
EU · EU-Funded · 2013-08-31 – 2016-12-31
£259,973
whole project
Predictive phenotypic assays to better predict drug-induced cardiotoxicityLeadInnovate UK · Feasibility Studies · 2013-07-01 – 2013-10-31 · with 1 other participant£23,250awarded
Predictive phenotypic assays to better predict drug-induced cardiotoxicityLead
Innovate UK · Feasibility Studies · 2013-07-01 – 2013-10-31 · with 1 other participant
£23,250
awarded
Biopta Limitedlead£23,250
Improving the Efficiency of Induced Pluripotent Cell (IPS) Generation in the DogBBSRC · Research Grant · 2012-02-01 – 2015-07-30 · with 3 other participants£282,385whole project
Improving the Efficiency of Induced Pluripotent Cell (IPS) Generation in the Dog
BBSRC · Research Grant · 2012-02-01 – 2015-07-30 · with 3 other participants
£282,385
whole project
University Of EdinburghleadIntervet-Shering Plough Animal HealthMerckReprocell Europe Ltd